High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
Gilead Sciences has delivered strong share price gains over the past five years, yet based on broad valuation checks it still screens as inexpensive relative to its fundamentals. For investors, the stock now sits in an interesting spot where a powerful HIV and oncology franchise is reflected in the price to some extent, but the broader valuation read still points to room for a more optimistic view than the market currently implies. Over the past 5 years, Gilead Sciences has returned about...
Gilead Sciences (GILD) is back in focus after the European Commission approved Trodelvy plus Keytruda for certain first line metastatic triple negative breast cancer patients, expanding the company’s oncology franchise in Europe. For investors tracking the bigger picture, Gilead Sciences’ 1 month share price return of 10.25% and year to date share price return of 21.78% point to firming momentum. The 1 year total shareholder return of 34.99% and 5 year total shareholder return of 145.70%...
Gilead Sciences (NasdaqGS:GILD) received expanded European Commission approval for Trodelvy in combination with Keytruda as a first-line treatment for metastatic triple-negative breast cancer across PD-L1 status in Europe. The decision establishes Trodelvy plus Keytruda as the first antibody-drug conjugate and immunotherapy combination approved for first-line metastatic TNBC across the European Union. The ruling broadens Trodelvy’s addressable patient population in Europe and further...
Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
Vivace Therapeutics has appointed Craig Gibbs as President and CEO as the company prepares to advance its lead candidate, VT3989, into a pivotal Phase 3 registrational trial. The clinical-stage biopharmaceutical company also named Ellen Lubman as Chief Business and Strategy Officer and...
These healthcare leaders are unlikely to suspend their dividend programs.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
The European Commission on Monday authorized Trodelvy combined with Merck’s (MRK) Keytruda for certain adults with previously untreated advanced or metastatic triple-negative breast cancer.
Gilead Sciences, Inc. (NASDAQ:GILD) produced an unusual earnings report in fiscal Q2 2026. Its commercial portfolio delivered double-digit growth, and yet the company posted one of the largest quarterly losses in its recent history. So where did the disconnect come from? It was created by more than $11 billion in acquired research and development expenses […]
Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to approximately $7.8 billion. The performance was primarily driven by continued growth across its HIV franchise, including Biktarvy and the newly launched Yeztugo. Gilead also raised its full-year product-sales guidance following the quarter. However, HIV products generated […]
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion. Yet, the income statement tells a considerably less flattering story. Gilead […]
The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday’s blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer’s (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in […]
In August 2026, Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead's global antibody-drug conjugate clinical development programs across multiple oncology indications. The partnership highlights how integrating AI-native computational pathology with clinical outcomes may help standardize biomarker assessment and refine precision medicine efforts in Gilead's oncology portfolio. Next, we'll examine how...
Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the company's revenue. The decision blocks a group of companies from importing cheaper foreign versions of Gilead's top HIV drug and selling them to American patients. For a company that relies heavily on a ...
Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500’s 13.1% gain. This might have investors contemplating their next move.
On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)’s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies’ 2022 collaboration. That broader agreement spans three programs, including clinical-stage CD123 x CD3 […]
A federal appeals court ruled Thursday that international versions of Gilead's HIV drug Biktarvy differ materially from FDA-regulated U.S. versions
Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across […]
Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of that progress is now priced into the...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
